REGULATORY

Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent

By Sakura Kono November 6, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Servier’s isocitrate dehydrogenase (IDH)-targeted glioma therapy Voranigo (vorasidenib) approved in September will not be included in Japan’s new drug price listings taking effect November 12, Jiho has learned. According to the company’s Japan arm, Nihon Servier, it decided not to…

To read the full story

Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen
November 6, 2025
GSK’s Blenrep, BMS’s Inrebic Absent from October Listing Roster
October 17, 2025

REGULATORY

LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025
Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…